Pharmacokinetics, Tolerability and Safety of NEX-18a

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

February 10, 2022

Study Completion Date

February 10, 2022

Conditions
Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
Interventions
DRUG

NEX-18a injection

"In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection."

DRUG

Azacitidine Injection

In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.

Trial Locations (2)

Unknown

Karolinska University Hospital Huddinge, Huddinge

Kliniska Forsknings och Utvecklings Enheten KFUE, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Nanexa AB

INDUSTRY

NCT05048498 - Pharmacokinetics, Tolerability and Safety of NEX-18a | Biotech Hunter | Biotech Hunter